| 3-Year Real-World Outcomes with the Swedish Adjustable Gastric Band™ in France. | |
| | |
MedLine Citation:
|
PMID: 23054572 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The study objective was to ascertain outcomes with the Swedish adjustable gastric band (SAGB) on an intention-to-treat basis in multiple centers across the French social health insurance system. SAGB results at 3-year follow-up are reported. The noncomparative, observational, prospective, consecutive cohort study design sought a 500-patient minimum recruitment geographically representative of continental France. Safety (adverse events [AEs], device-related morbidity, and mortality) and effectiveness (change in body mass index [BMI, kilograms per square meter], percentage excess weight loss, comorbidities, quality of life [QoL]) were assessed. Adjustable gastric band survival was calculated. Thirty-one surgeons in 28 multidisciplinary teams/sites enrolled patients between September 2, 2007 and April 30, 2008. SAGB was successfully implanted in 517 patients: 88.0 % female; mean age, 37.5 years; obesity duration, 15.3 years (baseline: mean BMI, 41.0; comorbidities, 773 in 74.3 % of patients; Bariatric Analysis and Reporting Outcome System (BAROS), 1.4; EuroQoL 5-Dimensions (EQ-5D), 0.61; EuroQoL-visual analog scale (EQ-VAS), 52.3). At 3 years: BMI, 32.2 (mean change, -9.0; p < 0.0001); excess weight loss, 47.4 %; comorbidities, 161 in 27.2 %; BAROS, 3.6 (+2.2, p < 0.0001); EQ-5D, 0.84 (+0.22, p < 0.0001); EQ-VAS, 73.4 (+21.4, p < 0.0001). SAGB-induced weight loss was associated with substantially improved QoL. One death occurred and was unrelated to the treatment. No AE was reported in 68.3 % of patients, and no confirmed device-related AE in 77.0 %. Overall AE rate was 0.19 per patient year. Device retention was 87.0 %. Analysis of patients lost to follow-up showed a nonsignificant effect on overall study results. In a prospective, consecutive cohort, "real-world", nationwide study, the Swedish Adjustable Gastric Band was found safe and effective at 3-year follow-up. |
| | |
Authors:
|
G Ribaric; J N Buchwald; G d'Orsay; F Daoud; |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-9-30 |
Journal Detail:
|
Title: Obesity surgery Volume: - ISSN: 1708-0428 ISO Abbreviation: Obes Surg Publication Date: 2012 Sep |
Date Detail:
|
Created Date: 2012-10-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9106714 Medline TA: Obes Surg Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Ethicon Endo-Surgery (Europe), European Surgical Institute, Hamburg, Germany, GRibaric@its.jnj.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cumulative Helicobacter pylori Eradication Therapy in Obese Patients Undergoing Gastric Bypass Surge...
Next Document: A 5-Year Experience of Laparoscopic Adjustable Gastric Banding in China.